A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53- Independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin

Cancer Research

Volumn 60, Issue 4, 2000, Pages 901-907

  Zhang, Zhongqiu ^a   Liu, Qing ^a   Lantry, Laura E ^a   Wang, Yian ^a   Kelloff, Gary J ^b   Anderson, Marshall W ^c   Wiseman, Roger W ^d   Lubet, Ronald A ^b   You, Ming ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; BENZO[A]PYRENE; DEXAMETHASONE; DOXORUBICIN; INOSITOL; METHYLNITROSOUREA; PACLITAXEL; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CONTROLLED STUDY; DRUG EFFICACY; FAMILIAL CANCER; FEMALE; GENE LOSS; GENE MUTATION; LUNG CARCINOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TEA; TRANSGENE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ALLELES; ANIMALS; ANTICARCINOGENIC AGENTS; DEXAMETHASONE; DOXORUBICIN; GENES, P53; GERM-LINE MUTATION; HUMANS; INOSITOL; LUNG NEOPLASMS; METHYLNITROSOUREA; MICE; MICE, TRANSGENIC; NITROSAMINES; PACLITAXEL; TEA;

EID: 0034652597     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassell, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., and Friend, S. H. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (Washington DC), 250: 1233-1238, 1990.
2. Srivastava, S., Zou, Z., Pirollo, K., Blattner, W., and Chang, E. H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature (Lond.), 348: 747-749, 1990.
3. Varley, J. M., Evans, D. G., and Birch, J. M. Li-Fraumeni syndrome - a molecular and clinical review. Br. J. Cancer, 76: 1-14, 1997.
4. Evans, S. C., and Lozano, G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol. Med. Today, 3: 390-395, 1997.
5. Li, F. P., and Fraumeni, J. F. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann. Intern. Med., 71: 747-752, 1969.
6. Hisada, M., Garber, J. E., Fung, C. Y., Fraumeni, S. F., Jr., and Li, F. P. Multiple primary cancers in families with Li-Fraumeni syndrome. J. Natl Cancer Inst., 90: 606-611, 1998.
7. Muller, H., Mosimann, S., Gebhardt, M., Scott, R., Spycher, M., and Weber, W. Tumor diseases in families of 600 breast cancer patients with special reference to familial adenocarcinomatosis and the Li-Fraumeni-/SBLA syndrome. Helv. Chir. Acta, 59: 239-245: 1992.
8. Kleihues, P., Schauble, B., zur Hausen, A., Esteve, J., and Ohgaki, H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am. J. Pathol., 150: 1-13, 1997
9. Nadav, Y., Pastorino, U., and Nicholson, A. G. Multiple synchronous lung cancers and atypical adenomatous hyperplasia in Li-Fraumeni syndrome. Histopathology, 33: 52-54, 1998.
10. Tomita, M., Tagawa, Y., Tsuji, T., Tsuji, H., and Ayabe, H. Cancer family syndrome in lung cancer - Li-Fraumeni syndrome in lung cancer. Nippon Rinsho, 53: 2716-2721, 1995.
11. Ko, L. J., and Prives, C. p53: puzzle and paradigm. Genes Dev., 10: 1054-1072, 1996.
12. Arrowsmith, C. H., and Morin, P. New insights into p53 function from structural studies. Oncogene, 12: 1379-1385, 1996.
13. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
14. Wang, X. W., and Harris, C. C. p53 tumor-suppressor gene: clues to molecular carcinogenesis. J. Cell. Physiol., 173: 247-255, 1997.
15. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356: 215-221, 1992.
16. Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., and Weinberg, R. A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol., 4: 1-7, 1994.
17. Donehower, L. A. The p53-deficient mouse: a model for basic and applied cancer studies. Semin. Cancer Biol., 7: 269-278, 1996.
18. Harvey, M,. McArthur, M. J., Montgomery, C. A., Butel, J. S., Bradley, A., and Donehower, L. A. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat. Genet., 5: 225-229, 1993.
19. Lavigueur, A., Maltby, V., Mock, D., Rossant, J., Pawson, T., and Bernstein, A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell. Biol., 9: 3982-3991, 1989.
20. Shimkin, M. B., and Stoner, G. D. Lung tumors in mice: application to carcinogenesis bioassay. Adv. Cancer Res., 21: 1-58, 1975.
21. Herzog, C. R., Lubet, R. A., and You, M. Genetic alterations in mouse lung tumors: implications for cancer chemoprevention. J. Cell. Biochem., 28/29S: 49-63, 1997.
22. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
23. Harris, C. C. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Environ. Health Perspect., 104: 435-439, 1996.
24. 1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate. Carcinogenesis (Lond.), 16: 2487-2492, 1995.
25. Hegi, M. E., Soderkvist, P., Foley, J. F., Schoonhoven, R., Swenberg, J. A., Kari, F., Maronpot, R., Anderson, M. W., and Wiseman, R. W. Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis (Lond.), 14: 803-810, 1993.
26. Wattenberg, L. W., and Estensen, R. D. Chemopreventive effects of myo-inositol and dexamethasone on benzo[a]pyrene and 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone-induced pulmonary carcinogenesis in female A/J mice. Cancer Res., 56: 5132-5135, 1996.
27. Xu, Y., Ho, C-T, Amin, S. G., Han, C., and Chung, F-L. Inhibition of tobacco-specific nitrosamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. Cancer Res., 52: 3875-3879, 1992.
28. Katiyar, S. K., and Mukhtar, H. Tea consumption and cancer. World Rev. Nutr. Diet., 79: 154-184, 1996.
29. Huang, M. T., Xie, J. G., Wang, Z. Y., Ho, C. T., Lou, Y. R., Wang, C. X., Hard, G. C., and Conney, A. H. Effects of tea, decaffeinated tea, and caffeine on UVB light-induced complete carcinogenesis in SKH-1 mice: demonstration of caffeine as a biologically important constituent of tea. Cancer Res., 57: 2623-2629, 1997.
30. Ahmad, N., Feyes, D. K., Nieminen, A. L., Agarwal, R., and Mukhtar, H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J. Natl. Cancer Inst., 89: 1881-1886, 1997.
31. Yang, C. S., Yang G. Y., Landau, J. M., Kim, S., and Liao, J. Tea and tea polyphenols inhibit cell hyperproliferation, lung tumorigenesis, and tumor progression. Exp. Lung Res., 24: 629-639, 1998.
32. Ozaki, K., Sukata, T., Yamamoto, S., Uwagawa, S., Seki, T., Kawasaki, H., Yoshitake, A., Wanibuchi, H., Koide, A., Mori, Y., and Fukushima, S. High susceptibility of p53(+/-) knockout mice in N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res., 58: 3806-3811, 1998.
33. Salgia, R., and Skarin, A. T. Molecular abnormalities in lung cancer. J. Clin. Oncol., 16: 1207-1217, 1998.
34. Harvey, M., Vogel, H., Morris, D., Bradley, A., Bernstein, A., and Donehower, L. A. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet., 9: 305-311, 1995.
35. Kemp, C. J., Donehower, L. A., Bradley, A., and Balmain, A. Cell, 74: 813-822, 1993.
36. Giaccone, G. Gemcitabine plus taxane combinations in non-small cell lung cancer. Semin. Oncol, 26 (Suppl. 4): 19-24, 1999.
37. Crown, J. A review of the efficacy and safety of docetaxel as monotherapy inmetastatic breast cancer. Semin. Oncol., 26 (Suppl. 3): 5-9, 1999.
38. Ozols, R. F. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Semin Oncol., 26 (Suppl. 2): 84-89, 1999.
39. Brown, J. M., and Wouters, B. G. Apoptosis, p53 and tumor cell sensitivity to anticancer agents. Cancer Res., 59: 1391-1399, 1999.